Cargando…

Developing in vitro expanded CD45RA(+) regulatory T cells as an adoptive cell therapy for Crohn's disease

BACKGROUND AND AIM: Thymus-derived regulatory T cells (T(regs)) mediate dominant peripheral tolerance and treat experimental colitis. T(regs) can be expanded from patient blood and were safely used in recent phase 1 studies in graft versus host disease and type 1 diabetes. T(reg) cell therapy is als...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canavan, James B, Scottà, Cristiano, Vossenkämper, Anna, Goldberg, Rimma, Elder, Matthew J, Shoval, Irit, Marks, Ellen, Stolarczyk, Emilie, Lo, Jonathan W, Powell, Nick, Fazekasova, Henrieta, Irving, Peter M, Sanderson, Jeremy D, Howard, Jane K, Yagel, Simcha, Afzali, Behdad, MacDonald, Thomas T, Hernandez-Fuentes, Maria P, Shpigel, Nahum Y, Lombardi, Giovanna, Lord, Graham M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819603/ https://www.ncbi.nlm.nih.gov/pubmed/25715355 http://dx.doi.org/10.1136/gutjnl-2014-306919

Ejemplares similares

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)
por: Probert, Christopher SJ, et al.
Publicado: (2018)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel
por: Din, Shahida, et al.
Publicado: (2020)

Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis
por: Kennedy, N. A., et al.
Publicado: (2016)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse
por: Arrieta, M C, et al.
Publicado: (2008)

Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition
por: Binion, D G, et al.
Publicado: (2008)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
por: Tursi, Antonio, et al.
Publicado: (2010)

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association
por: Kaplan, Gilaad G, et al.
Publicado: (2010)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis
por: Aherne, Carol M, et al.
Publicado: (2011)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
por: Cayatte, Corinne, et al.
Publicado: (2012)

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
por: Kruis, W, et al.
Publicado: (2009)

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Abnormally expressed ER stress response chaperone Gp96 in CD favours adherent-invasive Escherichia coli invasion
por: Rolhion, Nathalie, et al.
Publicado: (2010)

Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers
por: Roberts, Carol L, et al.
Publicado: (2010)

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Increased Epithelial Gaps in the Small Intestine Are Predictive of Hospitalization and Surgery in Patients With Inflammatory Bowel Disease
por: Turcotte, Jean-Francois, et al.
Publicado: (2012)

A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Factors affecting outcomes in Crohn's disease over 15 years
por: Cosnes, Jacques, et al.
Publicado: (2012)

Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease
por: Kiesslich, R, et al.
Publicado: (2011)

Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability
por: Cani, P D, et al.
Publicado: (2009)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
por: Hébuterne, Xavier, et al.
Publicado: (2013)

Therapeutic Effect of Vitamin D Supplementation in a Pilot Study of Crohn's Patients
por: Yang, Linlin, et al.
Publicado: (2013)

Propionyl-L-Carnitine is Efficacious in Ulcerative Colitis Through its Action on the Immune Function and Microvasculature
por: Scioli, Maria Giovanna, et al.
Publicado: (2014)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
por: Mayer, Lloyd, et al.
Publicado: (2014)

Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-Control questionnaire
por: Bodger, Keith, et al.
Publicado: (2014)

First Multicenter Study of Modified Release Phosphatidylcholine “LT-02” in Ulcerative Colitis: A Randomized, Placebo-Controlled Trial in Mesalazine-Refractory Courses
por: Karner, Max, et al.
Publicado: (2014)

Bacterial protein signals are associated with Crohn’s disease
por: Juste, Catherine, et al.
Publicado: (2014)

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
por: Cornillie, Freddy, et al.
Publicado: (2014)

Study of the Viral and Microbial Communities Associated With Crohn's Disease: A Metagenomic Approach
por: Pérez-Brocal, Vicente, et al.
Publicado: (2013)

Mouse Paneth cell antimicrobial function is independent of Nod2
por: Shanahan, Michael T, et al.
Publicado: (2014)

Higher Activity of the Inducible Nitric Oxide Synthase Contributes to Very Early Onset Inflammatory Bowel Disease
por: Dhillon, Sandeep S, et al.
Publicado: (2014)

Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2013)

Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease
por: Koelink, Pim J, et al.
Publicado: (2014)

Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer
por: Prorok-Hamon, Maelle, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_n7lmrgsvlqr7tmcjpt4e3g57dc